Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Endometrial

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    330 result(s) found for: Endometrial. Displaying page 6 of 17.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    EudraCT Number: 2018-001915-63 Sponsor Protocol Number: 13710 Start Date*: 2018-11-15
    Sponsor Name:University of Oxford / Clinical Trials and Research Governance
    Full Title: A randomised controlled pilot trial of the use of GnRH-antagonist pituitary suppression during medicated frozen-thawed embryo transfer (FET) cycles
    Medical condition: Infertility
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004872 10016398 Female infertility LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2014-005610-37 Sponsor Protocol Number: PROTEC1 Start Date*: 2015-05-07
    Sponsor Name:Central Manchester University Hospitals NHS Foundation Trust
    Full Title: PROgesterone Therapy for Endometrial Cancer prevention in obese women (PROTEC)
    Medical condition: Proliferation of the endometrium.
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-009429-26 Sponsor Protocol Number: local 997 (P06034) Start Date*: 2010-03-15
    Sponsor Name:FREE UNIVERSITY OF BRUSSELS
    Full Title: A PILOT STUDY TO EVALUATE THE EFFECT OF TRIGGERING FINAL OOCYTE MATURATION WITH GnRHa OR hCG ON ENDOMETRIAL RECEPTIVITY PARAMETERS AND THE LUTEAL PHASE IN OOCYTE DONORS
    Medical condition: Compare the endometrium of oocyte donors, who had final oocyte maturation with either hCG, Suprefact, followed by hCG 35 hours after triggering, Suprefact or Suprefact without luteal phase support....
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2004-002429-37 Sponsor Protocol Number: NSGO-EC-9501 Amendment 2 Start Date*: 2004-11-17
    Sponsor Name:Nordic Society for Gynecologic Oncology
    Full Title: A randomized trial of adjuvant treatment with radiation plus chemotherapy versus radiation alone in high-risk endometrial carcinoma NSGO-EC-9501 Amendment 2.
    Medical condition: Endometrial cancer stage I-III radically operated with high-risk factors (high-grade and deep myometrial infiltration, or serous or clear cell histology) that will receive adjuvant treatment with r...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003561-26 Sponsor Protocol Number: BAY1002670/15790 Start Date*: 2017-12-14
    Sponsor Name:Bayer AG
    Full Title: A randomized, parallel-group, double-blind and placebo-controlled, multicenter study to assess the efficacy and safety of vilaprisan in subjects with uterine fibroids
    Medical condition: Leiomyoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10016628 Fibroids LLT
    21.1 100000004864 10046784 Uterine fibroids LLT
    21.1 100000004864 10022794 Intramural leiomyoma of uterus LLT
    Population Age: Adults Gender: Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2017-004752-34 Sponsor Protocol Number: 53998 Start Date*: 2019-02-20
    Sponsor Name:Amsterdam University Medical Centers location AMC
    Full Title: Study of pembrolizumab combined with ataluren in Patients with metastatic pMMR and dMMR colorectal cancer adenocarcinomas or metastatic dMMR endometrial carcinoma: the ATAPEMBRO study.
    Medical condition: Mismatch repair deficient and proficient metestatic colorectal carcinoma and mismatch repair deficient metastatic endometrial carcinoma, stomach carcinoma and small bowel carcinoma.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-002824-26 Sponsor Protocol Number: VHIO17001 Start Date*: 2018-02-23
    Sponsor Name:Vall d' Hebron Institute of Oncology (VHIO)
    Full Title: Phase II trial of Pembrolizumab in combination with Doxorubicin in Advanced, Recurrent or Metastatic Endometrial Cancer (TOPIC)
    Medical condition: Advanced, Recurrent or Metastatic Endometrial Cancer
    Disease: Version SOC Term Classification Code Term Level
    12.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007129 Cancer-related morbidities HLGT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-005018-76 Sponsor Protocol Number: S60857 Start Date*: 2019-01-14
    Sponsor Name:University Hospitals Leuven
    Full Title: An open-label, single arm, prospective, multi-center, tandem two stage designed, phase II study to evaluate the efficacy of Fulvestrant in women with recurrent/metastatic estrogen receptor positive...
    Medical condition: endometrial stromal sarcoma uterine adenosarcoma endometrial carcinoma sex cord stromal tumors serous ovarian cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2020-004246-11 Sponsor Protocol Number: EDO-S101-1002 Start Date*: 2021-09-30
    Sponsor Name:Mundipharma Research Limited
    Full Title: A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics and Efficacy of Tinostamustine, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Patients with Ad...
    Medical condition: • Cohort 1: Relapsed/refractory Small Cell Lung Cancer • Cohort 2: Relapsed/refractory Soft Tissue Sarcoma • Cohort 3: Relapsed/refractory Triple-Negative Breast Cancer • Cohort 4: Relapsed/refr...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10041071 Small cell lung cancer stage unspecified LLT
    23.0 100000004864 10084066 Triple negative breast cancer metastatic LLT
    20.0 100000004864 10033130 Ovarian cancer NOS LLT
    21.0 100000004864 10014735 Endometrial cancer NOS LLT
    20.0 100000004864 10002479 Angiosarcoma NOS LLT
    21.1 100000004864 10057043 Dermatofibrosarcoma LLT
    21.1 100000004864 10015103 Epithelioid sarcoma NOS LLT
    20.0 100000004864 10024193 Leiomyosarcoma NOS LLT
    20.0 100000004864 10024631 Liposarcoma NOS LLT
    22.1 100000004864 10082807 Solitary fibrous tumor LLT
    20.0 100000004864 10042866 Synovial sarcoma NOS LLT
    21.1 100000004864 10025556 Malignant fibrous histiocytoma NOS LLT
    20.0 100000004864 10029276 Neurofibrosarcoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-003779-36 Sponsor Protocol Number: ICR-CTSU/2018/10066 Start Date*: 2019-10-11
    Sponsor Name:The Institute of Cancer Research
    Full Title: ATr inhibitor in combination with olaparib in gynaecological cancers with ARId1A loss or no loss
    Medical condition: Relapsed ovarian and endometrial clear cell carcinoma or relapsed other gynaecological cancers (endometriod (ovarian and endometrial), carcinosarcoma (ovarian and endometrial), cerviacal carcinoma ...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073268 Ovarian clear cell carcinoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009252 Clear cell endometrial carcinoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073269 Ovarian endometrioid carcinoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008224 Cervical adenocarcinoma LLT
    21.1 100000004872 10062718 Endocervical squamous metaplasia LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052204 Ovarian carcinosarcoma LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-019106-16 Sponsor Protocol Number: MK-1775009 Start Date*: 2010-05-31
    Sponsor Name:Netherlands Cancer Institute (NKI)
    Full Title: Phase II and Pharmacological Study with Wee-1 Inhibitor AZD1775 Combined with Carboplatin in Patients with p53 Mutated Epithelial Ovarian Cancer that Show Early Relapse (< 3 months) or Progressio...
    Medical condition: p53 mutated epithelial ovarian cancer (after first line standard therapy), non-small cell lung cancer, small cell lung cancer, cervical and endometrial cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014733 Endometrial cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041067 Small cell lung cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055094 Cervix cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-001290-78 Sponsor Protocol Number: 007697 Start Date*: 2012-01-17
    Sponsor Name:Barts Health NHS Trust
    Full Title: Diagnostic accuracy of MRI, diffusion-weighted MRI, FDG-PET/CT and Fluoro-ethyl-choline PET/CT in the detection of lymph node metastases in surgically staged endometrial and cervical carcinoma
    Medical condition: Endometrial and Cervical Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-004302-63 Sponsor Protocol Number: CLI20001/Lita005 Start Date*: 2020-12-15
    Sponsor Name:Litaphar Laboratorios S.L.
    Full Title: A multi-centre, open-label, single-arm study assessing the safety and efficacy of 5 mg of mifepristone for the treatment of endometriosis in reproductive-age women during two treatment cycles of 24...
    Medical condition: endometriosis in reproductive-age
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038604 - Reproductive system and breast disorders 10014778 Endometriosis PT
    Population Age: Adults Gender: Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-003301-16 Sponsor Protocol Number: 881/11 Start Date*: 2012-04-27
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: A Randomized Phase II Trial of Carboplatin-Paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced (stage III-IV) or recurrent endometrial cancer.
    Medical condition: endometrial cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014770 Endometrioid adenocarcinoma LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004221-41 Sponsor Protocol Number: BAY1002670/17541 Start Date*: Information not available in EudraCT
    Sponsor Name:Bayer HealthCare AG
    Full Title: A randomized, parallel-group, double-blind placebo-controlled and open label active-controlled, multi-center study to assess the efficacy and safety of vilaprisan in patients with uterine fibroids
    Medical condition: Leiomyoma
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10046784 Uterine fibroids LLT
    17.1 100000004864 10016628 Fibroids LLT
    17.1 100000004864 10022794 Intramural leiomyoma of uterus LLT
    Population Age: Adults Gender: Female
    Trial protocol: SE (Completed) DE (Completed) PT (Completed) NL (Completed) GB (Completed) FI (Completed) AT (Completed) CZ (Completed) HU (Completed) LT (Completed) BE (Completed) ES (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002855-48 Sponsor Protocol Number: BAY1002670/15789 Start Date*: 2017-07-12
    Sponsor Name:Bayer AG
    Full Title: A randomized, parallel-group, multicenter study to assess the efficacy and safety of vilaprisan in subjects with uterine fibroids
    Medical condition: Leiomyoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10046784 Uterine fibroids LLT
    20.0 100000004864 10016628 Fibroids LLT
    20.0 100000004864 10022794 Intramural leiomyoma of uterus LLT
    Population Age: Adults Gender: Female
    Trial protocol: IE (Completed) SE (Completed) CZ (Completed) HU (Prematurely Ended) FI (Completed) AT (Prematurely Ended) NO (Prematurely Ended) DE (Completed) ES (Prematurely Ended) GB (GB - no longer in EU/EEA) DK (Completed) BE (Completed) SK (Completed) LT (Completed) NL (Prematurely Ended) PT (Completed) BG (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-000821-31 Sponsor Protocol Number: 307969 Start Date*: 2004-11-16
    Sponsor Name:Schering AG
    Full Title: Multi-center, open, randomized, parallel group comparison of cycle control for seven cycles and endometrial safety in a subgroup for thirteen cycles of contraceptive patch SH P00331F (0.9 mg ethiny...
    Medical condition: Contraception
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: FI (Completed) ES (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2019-000275-16 Sponsor Protocol Number: 2693-CL-0304 Start Date*: 2019-09-03
    Sponsor Name:Astellas Pharma Global Development, Inc.
    Full Title: A Randomized, Placebo-controlled, Double-blind Phase 3 Clinical Study to Investigate the Long-Term Safety of Fezolinetant in Women Suffering from Vasomotor Symptoms (Hot Flashes) Associated with Me...
    Medical condition: Vasomotor Symptoms (Hot Flashes) Associated with Menopause
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004866 10020407 Hot flashes LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) PL (Completed) LV (Completed) ES (Completed) CZ (Completed) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-000689-13 Sponsor Protocol Number: HRT1vs2week.2018 Start Date*: 2018-07-11
    Sponsor Name:University hospital Brussel
    Full Title: Clinical pregnancy rate for frozen embryo transfer with HRT: a pilot study comparing 1 versus 2 weeks of treatment
    Medical condition: Subfertility in need of IVF and IVF-ICSI treatment
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004872 10042391 Subfertility LLT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004429-34 Sponsor Protocol Number: 2017.lipiodol.flush Start Date*: 2018-02-15
    Sponsor Name:UZ Brussel
    Full Title: Histological and Transcriptional Changes caused by Endometrial Flushing with Lipiodol: A Cross Over Study.
    Medical condition: Female subfertility
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004872 10042392 Subfertility (female) LLT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 24 10:58:03 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA